|
gptkbp:instanceOf
|
gptkb:drug
muscle relaxant
|
|
gptkbp:approvedBy
|
gptkb:Canada
gptkb:United_Kingdom
gptkb:United_States
|
|
gptkbp:ATCCode
|
gptkb:M03BA02
|
|
gptkbp:brand
|
gptkb:Soma
Vanadom
|
|
gptkbp:CASNumber
|
78-44-4
|
|
gptkbp:chemicalFormula
|
carbamate ester
|
|
gptkbp:compatibleWith
|
gptkb:Indonesia
gptkb:Norway
gptkb:Sweden
|
|
gptkbp:contraindication
|
porphyria
hypersensitivity to carisoprodol
|
|
gptkbp:discoveredBy
|
gptkb:Wallace_Laboratories
|
|
gptkbp:drugClass
|
carbamate
|
|
gptkbp:eliminationHalfLife
|
2 hours
meprobamate: 10 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasMolecularFormula
|
C12H24N2O4
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Carisoprodol
|
|
gptkbp:interactsWith
|
gptkb:beer
gptkb:benzodiazepines
opioids
other CNS depressants
|
|
gptkbp:introducedIn
|
1959
|
|
gptkbp:legalStatus
|
gptkb:Schedule_IV_controlled_substance_(US)
prescription only
|
|
gptkbp:mechanismOfAction
|
central nervous system depressant
|
|
gptkbp:metabolism
|
meprobamate
|
|
gptkbp:overdoseSymptoms
|
death
coma
respiratory depression
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescribedWith
|
gptkb:codeine
gptkb:aspirin
|
|
gptkbp:prescriptionForm
|
gptkb:tablet
oral suspension
|
|
gptkbp:riskFactor
|
addiction
withdrawal symptoms
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
dizziness
headache
drowsiness
dependence
abuse potential
|
|
gptkbp:synonym
|
gptkb:N-isopropylmeprobamate
|
|
gptkbp:usedFor
|
muscle spasms
musculoskeletal pain
|
|
gptkbp:bfsParent
|
gptkb:Schedule_IV
gptkb:Soma
|
|
gptkbp:bfsLayer
|
6
|